Literature DB >> 30359105

Prescription Drug Monitoring Program: Registration and Use by Prescribers and Pharmacists Before and After Legal Mandatory Registration, California, 2010-2017.

Aaron B Shev1, Garen J Wintemute1, Magdalena Cerdá1, Andrew Crawford1, Susan L Stewart1, Stephen G Henry1.   

Abstract

OBJECTIVES: To estimate the effect of California's prescription drug monitoring program's (PDMP) registration mandate on use of the PDMP.
METHODS: We evaluated the effect of California's mandatory PDMP registration law by fitting time series models on the percentage of clinicians registered for California's PDMP and the percentage of clinicians who were active PDMP users (users who created ≥ 1 patient prescription reports in a given month) from 2010 through 2017. We also compared PDMP use among early PDMP adopters (clinicians who registered > 8 months before the mandatory registration deadline) versus late adopters (clinicians who registered ≤ 8 months before the deadline).
RESULTS: Mandatory registration was associated with increases in active PDMP users: 53.5% increase for prescribers and 17.9% for pharmacists. Early adopters were 4 times more likely to be active PDMP users than were late adopters.
CONCLUSIONS: Mandatory registration was associated with increases in PDMP registration and use, but most new registrants did not become active users. Public Health Implications. Mandatory PDMP registration increases PDMP use but does not result in widespread PDMP usage by all clinicians prescribing controlled substances.

Entities:  

Mesh:

Year:  2018        PMID: 30359105      PMCID: PMC6236755          DOI: 10.2105/AJPH.2018.304704

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  7 in total

1.  Mandatory use of prescription drug monitoring programs.

Authors:  Rebecca L Haffajee; Anupam B Jena; Scott G Weiner
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

2.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  MMWR Recomm Rep       Date:  2016-03-18

3.  Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses: A Systematic Review.

Authors:  David S Fink; Julia P Schleimer; Aaron Sarvet; Kiran K Grover; Chris Delcher; Alvaro Castillo-Carniglia; June H Kim; Ariadne E Rivera-Aguirre; Stephen G Henry; Silvia S Martins; Magdalena Cerdá
Journal:  Ann Intern Med       Date:  2018-05-08       Impact factor: 25.391

4.  States With Prescription Drug Monitoring Mandates Saw A Reduction In Opioids Prescribed To Medicaid Enrollees.

Authors:  Hefei Wen; Bruce R Schackman; Brandon Aden; Yuhua Bao
Journal:  Health Aff (Millwood)       Date:  2017-04-01       Impact factor: 6.301

5.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.

Authors:  Yuhua Bao; Yijun Pan; Aryn Taylor; Sharmini Radakrishnan; Feijun Luo; Harold Alan Pincus; Bruce R Schackman
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

6.  Four States With Robust Prescription Drug Monitoring Programs Reduced Opioid Dosages.

Authors:  Rebecca L Haffajee; Michelle M Mello; Fang Zhang; Alan M Zaslavsky; Marc R Larochelle; J Frank Wharam
Journal:  Health Aff (Millwood)       Date:  2018-06       Impact factor: 6.301

7.  Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy.

Authors:  Richard M Reisman; Pareen J Shenoy; Adam J Atherly; Christopher R Flowers
Journal:  Subst Abuse       Date:  2009-05-01
  7 in total
  8 in total

1.  Perception of prescription drug monitoring programs as a prevention tool in primary medical care.

Authors:  Amie J Goodin; Joshua D Brown; Chris Delcher; Patricia R Freeman; Jeffery Talbert; Stephen G Henry; Dikea Roussos-Ross
Journal:  Res Social Adm Pharm       Date:  2019-03-26

2.  Advanced visualizations to interpret prescription drug monitoring program information.

Authors:  Scott G Weiner; Karen M Sherritt; Zoe Tseng; Jaya Tripathi
Journal:  Drug Alcohol Depend       Date:  2019-06-25       Impact factor: 4.492

3.  Advances in prescription drug monitoring program research: a literature synthesis (June 2018 to December 2019).

Authors:  Chris Delcher; Nathan Pauly; Patience Moyo
Journal:  Curr Opin Psychiatry       Date:  2020-07       Impact factor: 4.787

4.  Obstetrician-gynecologist perceptions and utilization of prescription drug monitoring programs: A survey study.

Authors:  Amie Goodin; Jungjun Bae; Chris Delcher; Joshua Brown; Dikea Roussos-Ross
Journal:  Medicine (Baltimore)       Date:  2021-01-08       Impact factor: 1.817

5.  Transversus abdominus plane blocks do not reduce rates of postoperative prolonged opioid use following abdominally based autologous breast reconstruction: a nationwide longitudinal analysis.

Authors:  Arhana Chattopadhyay; Jennifer Krupa Shah; Pooja Yesantharao; Vy Thuy Ho; Clifford C Sheckter; Rahim Nazerali
Journal:  Eur J Plast Surg       Date:  2022-10-04

6.  Evaluating Opioid Dispensing Rates among Pediatrics and Young Adults based on CURES Data Reporting in California from 2015-2019.

Authors:  Michael T Phan; Courtney Wong; Daniel M Tomaszewski; Zeev N Kain; Brooke Jenkins; Candice Donaldson; Michelle Fortier; Sun Yang
Journal:  J Contemp Pharm Prac       Date:  2021-03-03

7.  Opioid Prescribing After Implementation of Single Click Access to a State Prescription Drug Monitoring Program Database in a Health System's Electronic Health Record.

Authors:  Scott G Weiner; Kimiyoshi Kobayashi; Joshua Reynolds; Kit Chan; Rodd Kelly; Sarah Wakeman; Prabashni Reddy; Leonard D Young
Journal:  Pain Med       Date:  2021-10-08       Impact factor: 3.750

8.  Evaluating the Effects of Opioid Prescribing Policies on Patient Outcomes in a Safety-net Primary Care Clinic.

Authors:  Christopher L Rowe; Kellene Eagen; Jennifer Ahern; Mark Faul; Alan Hubbard; Phillip Coffin
Journal:  J Gen Intern Med       Date:  2021-06-25       Impact factor: 6.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.